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We describe a series of two-gene and bicistronic retroviral vectors that use the human MDR1 gene as a selectable
marker for the overexpression of a second heterologous gene in transduced cells. The vectors use Harvey murine sarcoma
virus sequences for viral expression and packaging functions and include sites for cloning foreign genes of interest under
the control of either an internal promoter (two-gene vectors) or an internal ribosome entry site (bicistronic vectors). To
characterize these vectors, we used neo as a reporter gene for foreign gene expression and as an independently selectable
marker for comparison with MDR1. Each of the vector constructions supported high-titer retrovirus production and transduc-
tion of mouse and human cell lines. Using MDR1–neo virus supernatants in parallel titering assays, we found that titers
based on colchicine resistance were 10- to 20-fold lower than titers based on G418 resistance, suggesting that MDR1 is
a more stringent selectable marker than neo in NIH 3T3 and KB-3-1 cell lines. Whereas neo gene expression with the two-
gene vectors was subject to host-specific limitations on internal promoter activity, the bicistronic vectors were highly active
in three cell lines tested. In K562 cells, using the bicistronic vector, selection with colchicine led to at least 20-fold higher
expression of the MDR1 gene product than did selection with G418, suggesting that the stringent MDR1 selection system
is very efficient for obtaining overexpression of foreign genes. Retroviral vectors carrying MDR1 as a selectable marker
plus a second, heterologous gene of interest could have widespread utility for in vitro and in vivo applications of gene
transfer technology, including gene therapy. q 1996 Academic Press, Inc.
INTRODUCTION pression of a marker gene can promote the long-term
expression of a cotransduced heterologous gene as well.
The efficient delivery and long-term expression of het-
For gene therapy applications, a selectable marker would
erologous genes in animal cells are central to the suc-
ideally work in vivo as well as in vitro.
cessful application of modern recombinant DNA technol-
The human multidrug resistance gene (MDR1) is well-
ogy to studies on gene expression, protein structure-
suited to the tasks of a selectable marker. MDR1 en-
function, and gene therapy. Retroviral vectors are among
codes a 1280-amino acid membrane glycoprotein called
the most widely used vehicles for gene transfer, but retro-
P-glycoprotein (Pgp) that acts as a multispecific drug
viruses are somewhat limited in their host range, they
transporter to prevent drug accumulation in resistant
can only infect dividing cells, and they exhibit relatively
cells (Kane et al., 1990). Overexpression of a transfected
low infectivity into some cell types (Miller et al., 1991;
or virally transduced MDR1 gene in normal host cells is
Markowitz et al., 1988a; Burns et al., 1993; Miller et al.,
sufficient for conferring resistance against a wide variety
1990; van Beusechem et al., 1994). Furthermore, expres-
of drugs, including colchicine and many chemotherapeu-
sion from retroviral long terminal repeats (LTRs) can be
tic agents (Pastan et al., 1988; Ueda et al., 1987). This
position-dependent and often decreases over the course
dominant multidrug resistance phenotype conferred by
of time in animals, either due to loss of short-lived trans-
MDR1 makes the gene an efficient selectable marker for
duced cells or because of transcriptional down-regula-
the transfer and expression of heterologous genes in
tion of transduced genes (McIvor et al., 1987; Palmer et
vitro (Kane et al., 1988, 1989). MDR1 is also an amplifiable
al., 1991; Hoeben et al., 1991; Jaenisch et al., 1981).
marker—by exposing MDR1-transfected cells to in-
The use of appropriate selectable markers can help
creasing concentrations of selective drug, it is possible
to overcome these difficulties with retroviruses. A strong
to select for amplified expression of MDR1 and overex-
selection pressure can enhance the isolation of rare
pression of linked heterologous genes is observed at the
gene transfer events in cell types that are difficult to
same time (Kane et al., 1988, 1989).
transduce. In addition, the continuous selection for ex-
MDR1 appears to be selectable in vivo as well. Lethally
irradiated mice reconstituted with MDR1-transduced
bone marrow show an enrichment for MDR1-marked1 To whom reprint requests should be addressed.
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cells after in vivo administration of taxol, a drug that describe and characterize a set of modified HaMSV/
MDR1 vectors encoding two genes either on indepen-selects for MDR1 gene expression (Podda et al., 1992;
Sorrentino et al., 1992). Furthermore, MDR1 is chemopro- dently transcribed mRNAs, using constitutive internal
promoters, or on a single bicistronic message via antective in vivo, since MDR1 transgenic mice and mice
reconstituted with MDR1-transduced bone marrow are IRES element. This work provides further insight into the
MDR1 selection system and it confirms IRES-mediatedresistant to bone-marrow-toxic doses of taxol (Hanania
et al., 1995a; Podda et al., 1992; Sorrentino et al., 1992; bicistronic expression as an efficient means for obtaining
coregulation of two genes.Mickisch et al., 1991). Similar results have been observed
with variants of human dihydrofolate reductase, which
MATERIALS AND METHODSprotects mouse marrow against methotrexate toxicity (Li
et al., 1994; Corey et al., 1990). One obvious extension Cell lines. NIH3T3 cells were maintained in Dulbecco’s
modified Eagle’s medium containing 10% bovine serumof chemoprotection therapy would be to transfer two or
more drug resistance genes at once, for the purpose of (Irvine Scientific), 5 mM glutamine, 50 units of penicillin
per milliliter, and 50 mg of streptomycin per milliliter. GPprotecting normal cells against a wide range of toxic
agents. Recent success at transferring MDR1 into human / E86 (Markowitz et al., 1988b) and GP / envAm12
(Markowitz et al., 1988a) packaging cell lines (providedCD34/ hematopoietic cells suggests that MDR1-related
gene therapy in humans is feasible (Hanania et al., by A. Bank, Columbia University) and the KB-3-1 epithelial
cell line (from M. Gottesman, National Cancer Institute)1995b; Ward et al., 1994).
To use MDR1 effectively as a selectable marker and/ were grown in the same medium but with 10% fetal bo-
vine serum. K562 cells were grown in RPMI mediumor as one of a battery of chemoprotective genes, better
vectors are needed for the efficient expression of MDR1 containing 10% fetal bovine serum.
Vector constructions. Vectors described in this workplus a second, heterologous gene of interest. The most
common approach to two-gene expression is to use a were derived from the pHaMA vector reported previously
(Metz et al., 1995). pHaMA carries an upstream HaMSVvector with two separate promoters that control expres-
sion of each gene independently (Miller and Rosman, LTR, a cis-acting retroviral packaging/dimerization signal
derived from VL30 elements, a full-length MDR1 cDNA1989). This theoretically allows regulated expression of
one of the genes if a tissue-specific, development-spe- (lacking a polyadenylation signal), unique XhoI, MluI, and
SalI restriction sites, and a retroviral polypurine tract fol-cific, or growth-specific promoter is used internally
(Macri and Gordon, 1994; Vile and Hart, 1993; Bodine et lowed by the downstream HaMSV LTR. Vectors pHa-
MASV and pHaMASVneo also were described previouslyal., 1994). A new approach to two-gene expression is to
use an internal ribosome entry site (IRES) inserted be- (Metz et al., 1995). The other two vectors containing inter-
nal promoters were constructed as follows: Each pro-tween two genes of interest (Adam et al., 1991; Ghattas
et al., 1991). The genes are expressed on a single, bicis- moter was isolated by polymerase chain reaction (PCR),
using an upstream primer that contained a MluI site attronic mRNA from which both gene products are trans-
lated independently. If one of the genes is continuously its 5* end and a downstream primer with a SalI site
at its 5* end. The promoters were isolated from genesselectable, as for MDR1, such coordinate transcription
should reduce the chance that expression of the heterol- encoding human phosphoglycerate kinase (PGK) (tem-
plate provided by J. Singer-Sam, City of Hope Nationalogous gene will be down-regulated over time.
We originally developed a MDR1-based selection sys- Medical Center; amplified nucleotides were0437 to/55
relative to the start of transcription, according to Singer-tem to express heterologous genes in a DNA-mediated
gene transfection setting (Kane et al., 1988, 1989). That Sam et al., 1984) or mouse cathepsin L (mCL) (template
provided by M. Gottesman; amplified nucleotides weresystem uses sequences from the Harvey murine sar-
coma virus (HaMSV) to control expression of MDR1 (Velu 0273 to /32 relative to the start of transcription, ac-
cording to Troen et al., 1991). PCR products containinget al., 1987). However, early forms of HaMSV/MDR1 vec-
tors were large and difficult to adapt for purposes of the promoter sequences were digested with MluI / SalI,
purified, and cloned into the MluI–SalI sites of pHaMA,retrovirus-mediated transduction of foreign genes (Velu
et al., 1987; Kane et al., 1989). We recently reported a producing vectors pHaMAPGK and pHaMAmCL. A cDNA
encoding the bacterial neomycin phosphotransferaseseries of reduced-size HaMSV/MDR1 vectors that sup-
port the production of high-titer retroviruses and can ex- gene (neo) was isolated as a PCR fragment with SalI and
XhoI sites at the 5* and 3 * ends, respectively (templatepress a second gene from an internal SV40 promoter
(Metz et al., 1995). We further demonstrated the applica- was RcRSV plasmid purchased from Invitrogen; amplified
nucleotides were 1898 to 2750 on the plasmid, 035 totion of HaMSV/MDR1 vectors for achieving inducible ex-
pression of a transduced gene in tumor cells (Gazit et /818 relative to the start of translation). The neo frag-
ment was cloned into the SalI site of pHaMAPGK andal., 1995) and for obtaining broad-range chemoprotection
of transduced cells using MDR1 plus a second chemo- pHaMAmCL, producing pHaMAPGKneo and pHaMAm-
CLneo.therapy resistance gene (Doroshow et al., 1995). We now
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To make pHaMAIRES, a fragment corresponding to unpublished results). This removed the entire MDR1
cDNA from the starting vectors and replaced it with neo.the IRES element of encephalomyocarditis virus (EMCV)
Virus production and titering. Virus production was aswas isolated by PCR with a SalI site engineered at the
described elsewhere (Metz et al., 1995). Briefly, DNAs5* end and a XhoI site included at the 3 * end (template
were transfected into the ecotropic packaging cell lineDNA containing the IRES element was kindly provided
GP / E86 by the DNA–CaPO4 coprecipitation method,by J. Majors, Washington University School of Medicine;
and cells were selected with 20 ng/ml colchicine (Sigma),amplified nucleotides were 2341 to 2929 of EMCV, num-
which selects for expression of the MDR1 gene, as pre-bering according to Ghattas et al., 1991). The template
viously reported (Kane et al., 1989; Metz et al., 1995).IRES contains a mutation at the natural EMCV translation
Selected cells were pooled into a producer population,start codon, creating a HindIII site; IRES-mediated trans-
ecotropic viruses were collected and then used to trans-lation initiates at the ATG encoded 10 nucleotides down-
duce the amphotropic packaging cell line GP / env-stream of this site (Ghattas et al., 1991). By PCR, we also
Am12. Transduced cells were selected with colchicineengineered a HpaI site immediately 3 * to the initiation
(20 ng/ml) and pooled into a producer population, andcodon. The IRES/vector sequence in the vicinity of the
amphotropic viruses were collected. For titering, 5 1 104ATG codon is: [AAGCTT] GCCACAACC ATG GTTAAC
(NIH 3T3) or 2 1 105 (KB-3-1) cells were plated inCTCGAG ...... ACGCGT GTCGAC, where the HindIII is
60-mm dishes on Day 0. On Day 1, 0.1 ml (NIH 3T3) orbracketed, unique XhoI, MluI, and SalI sites are under-
0.5 ml (KB-3-1) of 10-fold serial dilutions (undiluted tolined, the initiation ATG is double underlined, the HpaI
1004 diluted) of virus was added to cells in fresh mediumcloning site is in boldface type, and ...... signifies 158bp
containing 8 mg/ml polybrene. On Day 3, cells were incu-of nonessential vector sequence (Metz et al., 1995).
bated in fresh medium containing 60 (NIH 3T3) or 6 (KB-cDNAs to be translated must be blunt-end cloned at their
3-1) ng/ml colchicine and colchicine-resistant colonies5* end into the HpaI site, in-frame with the adjacent ATG.
were stained with methylene blue (0.5% in 50% ethanol)This produces a coding sequence with ATG-GTT codons
after 8–10 days. In some experiments, titers were deter-(met-val) appended to the 5* end of the cloned cDNA.
mined on the basis of colony formation in G418 (1.5 mg/Cloning at the 3 * end can use the HpaI site or any of
ml (total G418), Gibco-BRL), which selects for expressionthe downstream unique sites (XhoI, MluI, or SalI).
of the neo gene.For this report, either neo, as a reporter gene, or a
Cell transductions. For stable cell transductions, 1 1human glutathione peroxidase (GPx) cDNA, as a control
104 NIH 3T3 or KB-3-1 cells were incubated with a single
gene, was inserted into pHaMAIRES downstream of the
dose of virus in the presence of 8 mg/ml polybrene. Trans-
IRES element. Insert cDNAs were isolated by PCR as
ductions were performed at a multiplicity of infection
follows: (1) For neo, template was as above; the upstream
(m.o.i.) of 0.1, 1, or 10, according to titers determined on
primer was 5*-CAAG GTT AAC ATT GAA CAA GAT GG, NIH 3T3 cells. Two days later, fresh medium containing
where the HpaI site is in bold and the subsequent nucle- 60 (NIH 3T3) or 6 (KB-3-1) ng/ml colchicine was added,
otides are in-frame neo codons starting from nucleotide selection was continued for 10–14 days, and colchicine-/4; the downstream primer ended at /818 and included resistant cells were pooled for further analysis. In some
a XhoI site at its 5* end. The neo PCR product was di- transductions, cells were selected directly in G418 (1.5
gested with HpaI/ XhoI and cloned into the correspond- mg/ml) without prior exposure to colchicine. For trans-
ing sites of pHaMAIRES, giving pHaMAIRESneo. (2) For duction of K562 cells, 5 1 104 cells were exposed for 3
GPx, template was a cDNA for the human GPx-1 gene hr to 1 ml of the amphotropic pHaMAIRESneo virus at
(Chu et al., 1990); the upstream primer was 5*-CAGT TGC an m.o.i. of 1 or 8, in the presence of 8 mg/ml polybrene.
GCA TGC GCT CGG CTA GC, where the bold is a FspI Control cells were exposed only to growth medium (RPMI
(blunt-end cutter) site and the subsequent nucleotides plus 10% fetal bovine serum). After transduction, 3 ml of
are GPx codons starting from nucleotide /6 (relative to growth medium was added and the cells were incubated
the start of translation as reported in Chu et al., 1990); overnight. The following day, the cells were centrifuged
the downstream primer ended at /792 and included a and the cell pellets were resuspended in 0.1 ml growth
SalI site at its 5* end. The GPx PCR product was digested medium and transduced again in an identical fashion.
with FspI / SalI and cloned into the HpaI–SalI sites of Transduction proceeded consecutively for 3 days using
pHaMAIRES, giving pHaMAIRESPx. virus at an m.o.i. of 1 and then for 2 further days with
Finally, as additional control plasmids, we created virus at an m.o.i. of 8. Both transduced and control cells
pHaneoIRESPx and pHaneoSVPx. For these, PCR was were then allowed to recover by growing in fresh medium
used to isolate neo coding sequences with KspI and PacI for 3 days, after which 10,000 to 20,000 cells were plated
sites at the 5* and 3 * ends, respectively. The KspI–PacI in methylcellulose containing either 6 ng/ml colchicine or
fragment was inserted into the corresponding sites of 500 mg/ml G418. After 10–14 days of selection, individual
pHaMAIRESPx or pHaMASVPx (the latter vector contains colonies were picked and expanded in either colchicine
or G418.MDR1 plus an SV40 internal promoter driving GPx cDNA;
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Relative plating efficiencies. Stably transduced popula- of MDR1. The bicistronic vector, pHaMAIRES.X, carries
an IRES element derived from encephalomyocarditis vi-tions of cells, selected and growing continuously in col-
chicine, were plated at 500 or 1000 cells per 10-cm dish, rus to allow translation of two open reading frames from
a single transcript—the upstream MDR1 gene plus geneeither in no drug, in 80 (NIH 3T3), or 6 (KB-3-1) ng/ml
colchicine, or in 1.5 mg/ml G418. Cells were incubated X inserted downstream of the IRES. The two-gene vec-
tors, pHaMA(P).X, have an internal heterologous pro-for 7–14 days and plates were stained with methylene
blue. Relative plating efficiencies are expressed as (num- moter (P) residing downstream of MDR1 plus gene X
expressed under the control of that promoter. For theber of colonies in drug/number of colonies without drug)
1 100. promoters, we used the early promoter of SV40 virus,
and promoters for two cellular genes, human PGK andDNA and RNA analysis. DNA and RNA were isolated
from transduced cell lines by standard extraction meth- mouse procathepsin L (mCL). The cellular promoters
were chosen because of their ubiquitous expression pat-ods. DNAs were digested with HindIII / EcoR1 for hy-
bridization with the MDR1 probe, or with XbaI (NIH 3T3) terns in mammalian cell types, reasoning that such pro-
moters were likely to give relatively high constitutive ex-or PstI (KB-3-1) for hybridization with the neo probe. Di-
gested DNAs were separated on a 1% agarose gel and pression of foreign genes under their control (Lim et al.,
1987; Chauhan et al., 1991).transferred to Hybond-N membrane (Amersham). RNAs
were separated on a 1% agarose–formaldehyde gel and To characterize foreign gene expression with this set
of vectors, we used the neo gene as a reporter gene Xtransferred to Hybond-N by electroblotting. Filters were
hybridized with a 865-bp MDR1-specific probe (nt 1601– downstream of MDR1 (pHaMA(P)neo and pHaMAIRES-
neo in Fig. 1B). Additional vectors shown in Fig. 1 were2465 of the cDNA sequence, where /1 is the start of
transcription) for the HindIII / EcoRI digests and the used as controls in the experiments reported below. Bi-
cistronic vector pHaMAIRESPx (Fig. 1B) has MDR1 asMDR1 RNA hybridizations; a 580-bp neo-specific probe
(nt 106–685) for the XbaI digests and the neo RNAs; or the upstream gene and a human GPx downstream of the
IRES element. Bicistronic vector pHaneoIRESPx (Fig. 1C)a 220-bp neo-specific probe (nt 035 to /183) for the
PstI digests. Probes were labeled with [32P]dCTP using has GPx as the downstream gene but neo as the up-
stream gene and the selectable marker. Two-gene vectora random primer labeling kit from Ambion, Inc. Hybridiza-
tions were performed with 2 1 105 cpm/ml of probe in pHaneoSVPx has GPx under the control of an internal
SV40 promoter and neo as the upstream selectableRapid-Hyb hybridization buffer (Amersham) overnight at
657C. Filters were washed at a final stringency of 0.11 marker (Fig. 1C). Finally, an additional two-gene vector
(not shown) contains MDR1 in the upstream position andSSC (11 SSC is 150 mM NaCl, 15 mM sodium citrate,
pH 7.0)-0.1% sodium dodecyl sulfate at 657C. Filters were GPx under the control of an internal SV40 promoter. The
further application of the GPx-encoding vectors to geneexposed to XAR-5 film at 0807C using an intensifying
screen and to a Molecular Dynamics PhosphorImager transfer and chemoprotection studies will be described
elsewhere (unpublished results).screen for quantification with ImageQuant software.
Flow cytometry. Flow cytometry was performed as de- Virus titers. MDR1-based vectors are relatively large.
Genomic RNA derived from pHaMA is about 5820 nucleo-scribed elsewhere (Metz et al., 1995) using 4E3 mono-
clonal antibody (Signet Laboratories, Inc.) as primary an- tides long before the insertion of any heterologous se-
quences. The series of vectors shown in Fig. 1 encodetibody and fluorescein-conjugated goat anti-mouse IgG
(H / L) F(ab*)2 (Jackson ImmunoResearch) as secondary RNAs in the range of 6985 to 7234 nucleotides. We there-
fore wanted to determine the efficiency of virus produc-antibody.
tion with the two-gene and bicistronic vectors. Plasmids
pHaMASVneo, pHaMAPGKneo, pHaMAmCLneo, andRESULTS
pHaMAIRESneo were used to establish ecotropic and
amphotropic virus producer cell lines as described underVector constructions. We have developed a series of
retroviral vectors that use the MDR1 gene as a selectable Materials and Methods. Control lines were created with
pHaMA vector, carrying only MDR1 (Metz et al., 1995),marker. Details of the vector constructions are provided
under Materials and Methods and schematic drawings and with pLNCX vector, a common MoMLV-based retro-
viral vector carrying neo as a selectable marker (Millerof the relevant plasmids are shown in Fig. 1. The vectors
were derived from pHaMA, which uses a HaMSV back- and Rosman, 1989).
To obtain a series of independent producer cell lines,bone for the efficient production of MDR1 retroviruses
and the high-level expression of the MDR1 selectable up to four independent transfections or transductions
were performed with each new vector (see Materials andmarker in transduced cells (Metz et al., 1995; Doroshow
et al., 1995; Gazit et al., 1995; Pastan et al., 1988; Velu Methods). In addition, independent collections of virus
supernatants were made from each producer line andet al., 1987). In the current study, we modified pHaMA
by inserting either an internal promoter (two-gene vec- the titer of a given supernatant collection was determined
more than once for some of the collections. Table 1tors) or an IRES element (bicistronic vectors) downstream
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FIG. 1. Linear representations of retroviral vectors. All vectors include HaMSV LTRs flanking a full-length MDR1 cDNA lacking its own polyadenyla-
tion signal (MDR/A). (A) Maps of the basic HaMSV/MDR1 vectors. pHaMA(P).X represents two-gene vectors with various internal promoters (P) and
a unique Sal1 site (S) for cloning gene X of interest. pHaMAIRES.X represents the bicistronic vector with an internal ribosome entry site (IRES) and
cloning sites as indicated under Materials and Methods. (B) Maps of vectors containing neo or the glutathione peroxidase cDNA (GPx) in the X
position. Black bars above the maps show the probes used for Southerns and Northerns. Dashed lines below the maps indicate the expected sizes
and origins of mRNAs transcribed from the vectors. ATGs on the bicistronic message represent the two start sites for translation of upstream and
downstream genes. (C) Maps of control vectors containing neo in place of MDR1 in the upstream position of a bicistronic (left) and a two-gene
(right) vector, both with GPx in the X position. E, EcoRI; H, HpaI; Hi, HindIII; M, MluI; P, PstI; S, Sal1; X, XhoI.
shows a summary of titering data obtained from multiple in Table 1). This probably reflected variable expression
levels resulting from different vector integration sitesproducer lines, multiple supernatant collections, and
multiple titer determinations for each vector. For a given within each population of producer cells. For any given
producer line, titers were more consistent and generallyvector, average titers obtained from independent pro-
ducer lines were somewhat variable, with 2- to 10-fold varied only 2- to 3-fold between collections taken on
different days. This was true even if the producer cellsdifferences between the highest- and lowest-titer lines
(data included within the aggregate ranges and averages were maintained in continuous culture for 5–7 days with-
TABLE 1
Virus Titers wtih Two-Gene and Bicistronic MDR1 Vectors
Ecotropica Average titer (range) Amphotropicb Average titer (range)
Vector [total no.]c [total no.]c
pHaMAIRESneo 2.7 1 105 (3.0 1 104 –1.8 1 106) [10] 5.4 1 104 (9.0 1 103 –1.3 1 105) [9]
pHaMASVneo 1.1 1 105 (4.5 1 104 –2.8 1 105) [5] 6.3 1 104 (1.0 1 104 –2.6 1 105) [12]
pHaMAPGKneo 5.4 1 104 (3.8 1 104 –7.0 1 104) [2] 1.4 1 105 (2.8 1 104 –2.6 1 105) [2]
pHaMAmCLneo 2.9 1 105 (2.8 1 104 –9.0 1 105) [5] 3.6 1 104 (1.9 1 104 –1.0 1 105) [11]
pHaMA 2.0 1 106 (2.0 1 104 –1.1 1 107) [5] 6.8 1 105 (6.0 1 103 –4.9 1 106) [18]
pLNCX 7.5 1 106 (2.0 1 106 –8.5 1 106) [10] 7.1 1 105 (2.0 1 105 –1.5 1 106) [9]
a Titers (cfu/ml) for ecotropic virus collected from GP / E86 producer cells.
b Titers (cfu/ml) for amphotropic virus collected from GP / envAm12 producer cells.
c Average titers (ranges in parentheses) obtained from multiple producer lines, multiple supernatant collections from each producer line, and
multiple titer determinations for each collection. The total number of titering assays is indicated in brackets.
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TABLE 2 structions appeared to be comparable to virus production
with more commonly used MoMLV-based vectors.G418 vs Colchicine Titers on NIH3T3 Cells
Comparison of NIH 3T3 titers and KB-3-1 titers. In ex-
Vector G418a Colchicineb G418/COLc periments described below, titers derived from NIH 3T3
cells were used to determine multiplicities of infection
Expt. 1 for transducing the human epidermoid KB-3-1 cell line.
pHaMAIRESneo 1.0 1 105 1.1 1 104 9 However, the efficiency of transduction into human cells
pHaMASVneo 2.8 1 105 1.8 1 104 16 is generally lower than that into murine cells when
pHaneoSVPx 2.1 1 105 0 — MoMLV-based packaging cell lines are used for the pro-
duction of virus (Markowitz et al., 1988a; Miller et al.,
Expt. 2
1991). To determine the relative transduction efficiencies
pHaMAIRESneo 1.0 1 106 4.7 1 104 21 of human KB-3-1 cells and mouse NIH 3T3 cells using
pHaMAIRESPx 0 9.0 1 104 — amphotropic HaMSV/MDR1 retroviruses, parallel titering
pHaneoIRESPx 9.0 1 105 0 —
assays were performed on these two cell lines. ResultspHaMASVneo 2.8 1 105 1.2 1 104 23
are shown in Table 3. As expected, titers determined on
a Titers (cfu/ml) based on G418 resistance. KB-3-1 cells were generally 20- to 100-fold lower than
b Titers (cfu/ml) based on colchicine resistance. titers of the same viruses determined on NIH 3T3 cells.
c Ratio of G418- to colchicine-resistant cfu/ml. In most cases, the same difference in titer was observed
whether colchicine or G418 was used as the selective
agent (for example, see pHaMAIRESneo titers in Table
out intervening passage of the cells (data not included 3), suggesting that the titers were a true reflection of
in Table 1). relative transduction efficiencies and not a result of differ-
Comparison of colchicine titers and G418 titers. We ent drug selection characteristics in the two cell lines.
noticed during this initial characterization of virus produc- However, when G418 was used to titer pHaMASVneo,
tion that in side-by-side assays, titers obtained from an unusually low titer was obtained on KB-3-1 cells. This
pLNCX virus were routinely 5- to 10-fold higher than probably reflected a relatively low level of neo gene ex-
those obtained from MDR1-based vectors. Since titers pression from the SV40 promoter in KB-3-1 cells (see
are defined in terms of the transduction and functional
expression of the selectable marker gene, we thought it
TABLE 3possible that the differences between pLNCX and MDR1-
based titers were not due to greater virus production by Titers on NIH3T3 Cells vs KB-3-1 Cells
pLNCX producer cell lines, but rather were a reflection
Titer (cfu/ml)of differences between a G418-resistant colony forming
assay and a colchicine-resistant colony forming assay.
Vector Selectiona NIH3T3 KB-3-1
To test this possibility directly, viruses that encoded
both MDR1 and neo were used in side-by-side titering pHaMAIRESneo
Expt. 1 COL 1.1 1 104 690assays that used either colchicine or G418 as the selec-
G418 1.0 1 105 5.8 1 103tive agent for measuring colony forming units. Results
Expt. 2 COL 1.9 1 104 700are shown in Table 2. Regardless of the configuration of
COL 4.7 1 104 420
the two marker genes within the virus, G418-based titers Expt. 3 G418 1.0 1 106 1.5 1 103
were always about 10- to 20-fold higher than colchicine- pHaMASVneo
Expt. 1b COL 1.8 1 104 530based titers of the same virus supernatant. This was
G418 2.8 1 105 620particularly significant for the pHaMAIRESneo construc-
Expt. 2b COL 1.2 1 104c 360ction, in which MDR1 and neo were encoded on the same
G418 2.8 1 105 81
LTR-driven transcript. In this case, differences in titers pHaMAPGKneo
could not have been due to different levels of mRNA Expt. 1 COL 2.8 1 104 1.0 1 103
Expt. 2 COL 2.6 1 105 490cexpression for the two genes. There could have been
pHaMAmCLneodifferent translational efficiencies for the upstream and
Expt. 1 COL 1.6 1 104 680cdownstream genes, but placement of neo into the up-
Expt. 2 COL 4.3 1 104 610
stream position in a bicistronic vector (pHaneoIRESPx) pHaMAIRESPx COL 9.0 1 104 3.6 1 103
or under the control of the LTR in a two-gene vector pHaneoIRESPx G418 9.0 1 105 1.4 1 104
(pHaneoSVPx) did not significantly affect virus titer.
a Indicates the drug used to determine titer, colchicine (COL), orThese results suggest that titers based on colchicine-
G418.
resistant colony formation are generally about 10-fold b Values for NIH 3T3 cells are from Table 2.
lower than those based on G418-resistant colony forma- c The average of two to three independent titering assays. All other
titers were performed once.tion. Furthermore, virus production with our vector con-
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below). Taken together, the results in Table 3 indicate
that transduction of KB-3-1 cells was at the 1–5% level
according to titers determined on NIH 3T3 cells.
Foreign gene expression with bicistronic and two-gene
vectors. Experiments measuring G418-resistant colony
formation (titers) with our MDR1-based vectors sug-
gested that the heterologous neo gene could be effi-
ciently transduced and expressed along with MDR1 (Ta-
bles 2 and 3). To assess neo expression more carefully,
NIH 3T3 cells or KB-3-1 cells were transduced with eco-
tropic or amphotropic virus, respectively, corresponding
to pHaMAIRESneo, pHaMASVneo, pHaMAPGKneo, and
pHaMAmCLneo vectors. Transductions were performed
at a m.o.i. of 1 or 10 according to colchicine-resistant
titers determined on NIH 3T3 cells. Populations of trans-
duced cells were isolated by selection in colchicine as
described under Materials and Methods.
To analyze MDR1 and neo gene expression on a per-
cell basis, relative plating efficiencies in colchicine and
G418 were determined for each of the populations of
transduced cells. Results are shown in Fig. 2. In NIH 3T3
cells, equivalent plating efficiencies were observed in
colchicine and G418, indicating that both MDR1 and neo
were expressed in all transduced cells, with each of
the retroviral constructions tested. Likewise, KB-3-1 cells
transduced with pHaMAIRESneo, encoding MDR1 and
FIG. 2. Relative plating efficiencies. NIH 3T3 (top) or KB-3-1 (bottom)neo on a single bicistronic mRNA, were resistant to both
cells were transduced at an m.o.i. of 1 or 10 with ecotropic (NIH 3T3)colchicine and G418. However, when neo was under the
or amphotropic (KB-3-1) retroviruses. IRESneo cells have MDR1 andcontrol of an internal promoter in transduced KB-3-1 cells,
neo encoded on the same mRNA, with neo under the control of an
very few or none of the colchicine-resistant cells were internal ribosome entry site. SVneo, PGKneo, and mCLneo have MDR1
able to grow in G418, even when the concentration of and neo encoded on separate mRNAs, with neo under control of SV40,
human phosphoglycerate kinase, or mouse cathepsin L promoter, re-G418 in the growth medium was reduced twofold. The
spectively. See Materials and Methods and Fig. 1 for details of con-neo expression appeared to be slightly better with pHa-
structions. Populations of transduced cells were selected with colchi-MASVneo than with the other vectors, but at most 29%
cine as indicated under Materials and Methods and then plated in no
of transduced cells were G418 resistant with this vector drug, colchicine (80 ng/ml for NIH 3T3 cells, 6 ng/ml for KB-3-1 cells),
(Fig. 2). or G418 (0.8 or 1.5 mg/ml). Relative plating efficiencies were calculated
as (number of colonies in drug/number of colonies without drug) 1To determine the basis for cell-line-specific G418 re-
100. For NIH 3T3 cells, h, colchicine; j, 1.5 mg/ml G418. For KB-3-1sistance in cells transduced with two-gene vectors, the
cells, h, colchicine; j, 0.8 mg/ml G418; ¿, 1.5 mg/ml G418.following experiments were performed on populations of
transduced cells. First, the presence of transduced DNAs
was confirmed by Southern hybridization (Fig. 3A). MDR1 promoters, Northern analysis was performed on RNA de-
rived from transduced NIH 3T3 cells and KB-3-1 cells.sequences were detected in all populations of trans-
duced NIH 3T3 and KB-3-1 cells. Normalization of MDR1 Representative results are shown in Fig. 3B. There were
substantial levels of subgenomic, neo-specific mRNA ex-hybridization signals to those of cross-reacting endoge-
nous sequences indicated that average proviral copy pressed from internal promoters in all populations of
transduced NIH 3T3 cells. That was clearly not the casenumber in both transduced cell types was low, even at
the higher m.o.i. used in these experiments. The neo in KB-3-1 transductants, which had little or no detectable
subgenomic mRNA encoding neo. The neo was encodedsequences were present in all populations analyzed
(data not shown for NIH 3T3 cells; representative results by the single full-length message in cells transduced with
pHaMAIRESneo virus (the large, genome-length mRNAsfor KB-3-1 cells shown in Fig. 3A). MDR1- and neo-spe-
cific bands were of the expected sizes, indicating that appeared to be slightly degraded in some samples in
this experiment, accounting for the relatively low signal inno gross DNA rearrangements had occurred during
transduction or colchicine selection. Therefore, intact the pHaMAIRESneo lane in NIH 3T3 cells). These results
suggest that despite the presence of neo DNA, trans-transduced sequences were present at similar copy
number in NIH 3T3 and KB-3-1 cells. duced KB-3-1 cells did not efficiently express neo mRNA
from internal promoters. NIH 3T3 cells with comparableSecond, to measure gene expression from internal
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In the second experiment, mass cultures of KB-3-1
cells were transduced with each of the two-gene viruses
and cells were selected immediately in G418 without
prior exposure to colchicine. Again, G418-resistant cells
were obtained in all cases, but always fewer than when
colchicine was used for the selection (data not shown).
Taken together, the results of G418 resistance assays
and Northern analysis suggest that gene expression from
the internal promoters of two-gene vectors was relatively
inefficient in KB-3-1 cells.
Transduction of K562 leukemia cells. To demonstrate
further the power of the MDR1 selection system, we used
the pHaMAIRESneo virus to transduce K562 leukemia
cells. Cells were selected directly with either colchicine
or G418 and individual clones were analyzed for their
expression of the MDR1 gene product (Pgp) on the cell
surface. The controls in the flow cytometry were a non-
transduced K562 clone and a clone from cells that were
exposed to virus under transduction conditions but were
not selected with either drug. Results of flow cytometry
are shown in Fig. 4. Overall, transduction efficiency was
FIG. 3. Southern and Northern analysis of transduced cells. Genomic
relatively low into these cells (1–2%). Nevertheless, cellsDNA and total RNA were isolated from populations of transduced cells
selected directly with colchicine expressed very high lev-and treated as described under Materials and Methods. (A) Photo-
graphs of autoradiograms from Southern analysis of transduced NIH els of Pgp, at least 50-fold over the unselected control
3T3 cells and KB-3-1 cells, as indicated below each panel. Control colony (Fig. 4A). When cells were first selected with
populations were nontransduced parent cells and cells transduced G418, however, Pgp expression was no higher than that
with retrovirus encoding MDR1 but not neo (pHaMA). Hybridizations
in the unselected colony in three clones (not shown) andwere performed with MDR1- or neo-specific probes, as labeled in bold.
in two others was about 20-fold lower than that in theNumbers between the panels indicate the positions of size markers
(bp). The arrow points to bands in the MDR1 hybridizations that corre- clones selected with colchicine (Fig. 4B). Preliminary
spond to transduced MDR1 sequences. (B) Photographs of autoradio- measurements of neomycin phosphotransferase protein
grams from Northern analysis of transduced cells. Control populations
levels suggested that neo expression in colchicine-se-were nontransduced cells. Hybridizations were performed with neo-
lected cells was slightly higher than its expression inspecific probe. The positions of 28S and 18S ribosomal RNAs are
indicated. The arrow points to the position of subgenomic neo-specific G418-selected cells (K.A.W. and J.H.D., unpublished ob-
mRNA. servations). These results again demonstrate that both
the upstream and downstream genes can be expressed
in cells transduced with bicistronic virus. They further
transduced gene copy number utilized the internal pro-
suggest that the MDR1 gene is a powerful selectable
moters very efficiently.
Finally, we thought it possible that selection for MDR1
expression with colchicine might have selected against neo
TABLE 4
expression in KB-3-1 cells. To address this possibility, we
G418 vs Colchicine Titers with Two-Gene Vectorsperformed two types of experiments. The first was a stan-
dard titering assay on KB-3-1 cells using G418 as the select-
Vector Cell linea G418b Colchicinec G418/COLd
ing agent to score colony forming units. As shown in Table
4, G418-resistant colonies could be selected with each of pHaMASVneoe KB-3-1 620 530 1.2
NIH 3T3 2.8 1 105 1.8 1 104 16the two-gene vectors if there was no prior exposure of cells
pHaMASVneoe KB-3-1 81 360 0.2to colchicine. However, G418-based titers on KB-3-1 cells
NIH 3T3 2.8 1 105 1.2 1 104 23were lower than or about the same as colchicine-based
pHaMAPGKneo KB-3-1 107 910 0.1
titers on those cells, despite the fact that colchicine is a more NIH 3T3 4.4 1 105 1.8 1 104 24
stringent selectable marker than G418. This is in contrast to pHaMAmCLneo KB-3-1 1050 1020 1.0
NIH 3T3 1.2 1 106 8.5 1 104 14the 16- to 23-fold higher G418-based titers of the same
vector stocks measured on NIH 3T3 cells. Furthermore,
a Indicates cell line on which titers were determined.G418-based titers determined on KB-3-1 cells were 450- to b Titers (cfu/ml) based on G418 resistance.
4100-fold lower than G418-based titers determined on NIH c Titers (cfu/ml) based on colchicine resistance.
3T3 cells, far lower than expected from a 1–5% transduction d Ratio of G418- to colchicine-resistant cfu/ml.
e From Table 3.efficiency of KB-3-1 cells relative to NIH 3T3 cells.
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FIG. 4. Flow cytometry of K562 cells transduced with pHaMAIRESneo retrovirus. K562 cells were transduced with pHaMAIRESneo retrovirus as
described under Materials and Methods and then selected with either colchicine or G418. Individual colonies from each selection were isolated,
expanded, and flow cytometry was performed to detect cell-surface expression of Pgp, the product of the MDR1 gene. (A) Two colonies selected
with colchicine. (B) Two colonies selected with G418. Controls in both panels were nontransduced K562s or a clone that was transduced but not
exposed to any selection, as indicated in parentheses.
marker for achieving overexpression of itself and of for- further characterization of the HaMSV/MDR1 selection
eign genes in K562 cells. system. We used neo as a reporter for foreign gene ex-
pression and as an independently selectable marker for
comparison with MDR1.DISCUSSION
Titers with each of our two-gene and bicistronic vec-
We have described a series of two-gene and bicis- tors were in the range of 2.8 1 104 –1.8 1 106 for eco-
tronic retroviral vectors that use MDR1 as a selectable tropic virus and 9.0 1 103 –2.6 1 105 for amphotropic
marker for expressing a second foreign gene at high virus (Table 1). While this was lower than titers obtained
levels in transduced cell lines. Each of these vectors
in parallel experiments with the pLNCX vector, this differ-
uses HaMSV sequences to encode the cis-acting ele-
ence was probably due to the different assay conditions
ments required for retroviral packaging and gene expres-
used to titer the respective viruses. Using retroviruses
sion. We used HaMSV-derived vectors because they
that encoded MDR1 and neo on a single bicistronichave proven to be extremely effective for the expression
mRNA or on two independent mRNAs, we found that viralof MDR1 in transfected and transduced cells (Kane et
titers based on colchicine resistance were routinely 10-al., 1988, 1989; Metz et al., 1995; Pastan et al., 1988;
to 20-fold lower than titers based on G418 resistanceSorrentino et al., 1992; Podda et al., 1992). We have re-
(Table 2). On the one hand, these results illustrate thecently described reduced-size versions of HaMSV/MDR1
inherent difficulties with using a functional assay forvectors that retain their ability to overexpress MDR1 and
measuring virus titers. On the other hand, the biologicallysupport the production of high-titer ecotropic and ampho-
relevant property of HaMSV/MDR1 retroviruses is theirtropic retroviruses (Metz et al., 1995). Furthermore, there
ability to transduce MDR1 in a fashion that producesmight be safety and efficiency advantages to using
multidrug resistant cells, so it is that property which weHaMSV-based vectors because of the reportedly small
need to evaluate.size of their VL30-derived packaging/dimerization do-
An additional explanation for low and variable colchi-main and the lack of any homology between these se-
cine-based titers could come from the fact that there arequences and those of gag, pol, and env genes used in
cryptic splice donor and acceptor sites within the MDR1common packaging cell lines (Torrent et al., 1994). VL30
coding sequence (Sorrentino et al., 1995). Internallyelements also might impart enhanced stability on the
spliced MDR1 mRNA produces a nonfunctional genegenomic RNA expressed from HaMSV vectors (Meric and
product, but the neo portion of the same mRNA shouldGoff, 1989; Torrent et al., 1994).
be intact. However, the internal splice sites are utilizedWe have previously demonstrated that MDR1 is a pow-
at most about 50% of the time (Fig. 3 and Metz et al.,erful selectable and amplifiable marker for the overex-
1995; Sorrentino et al., 1995), so that colchicine titerspression of foreign genes in transfected cell lines (Kane
should only be reduced about twofold relative to G418et al., 1989). We recently reported a two-gene HaMSV/
titers by this mechanism. The variable utilization of cryp-MDR1 retrovirus and showed that MDR1 can be used
tic splice sites could in part account for variable titersfor this same purpose in the context of retroviral trans-
duction as well (Metz et al., 1995). The current work is a between vector stocks, however.
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Our data suggest that actual virus production and gene al., 1994). The primary difference between these other
vectors and the ones reported here is the absence oftransduction with MDR1-based vectors are similar to
those with nonselectable MFG vectors or neo-based vec- over 3000 bp of nonessential HaMSV/VL30 sequences
from our vectors (this work and Metz et al., 1995). Thetors (Dranoff et al., 1993; Miller and Rosman, 1989), but
that colchicine resistance is a more stringent selection larger MDR1-based bicistronic vectors have been used
to express either human metabolic enzymes as poten-pressure than G418 resistance. By stringent, we mean
that at the concentration of colchicine required to kill tially therapeutic genes (Aran et al., 1994; Sugimoto et
al., 1995a), or herpes simplex virus thymidine kinase (TK)nontransduced cells, the only transduced cells that sur-
vive are those expressing high levels of the MDR1 gene as a negative selectable marker and a safeguard against
introducing MDR1 into malignant cells (Sugimoto et al.,product. Under selective G418 conditions, however,
much lower levels of neo expression appear to be suffi- 1995b). Interestingly, vincristine (a selection for MDR1
expression) is a two- to threefold more stringent selectioncient for survival of transduced cells. One consequence
of the different stringencies of selection is that MDR1- than HAT (a selection for TK expression) for cells
transfected with a MDR1–IRES–TK vector (Sugimoto etlinked genes are expressed at high levels when colchi-
cine is the selective agent, but neo-linked genes are al., 1995b). Transfected cells selected with HAT express
correspondingly lower levels of Pgp, on average, thanexpressed only at low or moderate levels when G418 is
used for selection. cells selected in more stringent vincristine conditions.
Moreover, Sugimoto et al. (1995a) suggest that if a strin-Results with pHaMAIRESneo in K562 cells are consis-
tent with the idea that MDR1-based selection is more gent selectable marker is placed downstream of an IRES,
then high expression of an upstream gene can be ob-stringent than neo-based selection. When transduced
cells were initially selected with colchicine, the level of tained. These results are all consistent with our findings
that colchicine was a more stringent selection than G418Pgp expression on the cell surface was at least 20-fold
higher than that when cells were selected with G418 (Table 2) and that low-stringency G418 selection of K562
transductants led to low Pgp expression (Fig. 4).(Fig. 4). At the same time, the level of neomycin phospho-
transferase in colchicine-selected cells appeared to be The advantage of using a bicistronic vector, particu-
larly with a strong selectable marker like MDR1, is thatcomparable to or slightly elevated over that seen in G418-
selected cells. Therefore, colchicine selection led to high expression of two genes is under the regulation of a
single promoter. If MDR1 proves to be an efficient se-expression of both MDR1 and neo, while G418 selection
led to elevated expression only of neo. The simplest ex- lectable marker in vivo, as appears to be the case in
mice (Hanania et al., 1995a; Podda et al., 1992; Sorrentinoplanation for these results is that colchicine places a high
selective pressure on transduced cells, thus demanding et al., 1992), then this could be one way to circumvent
the problems of position-dependent expression and tran-high MDR1 expression for cell survival and achieving
concomitant elevated expression of the linked neo gene. scriptional down-regulation often encountered with ret-
roviral vectors (Jaenisch et al., 1981; Hoeben et al., 1991;G418 imposes a relatively low selective pressure de-
manding only moderate neo expression for survival, with Palmer et al., 1991). The disadvantage of bicistronic vec-
tors is that they do not allow expression of two genes toonly low expression of the linked MDR1 gene.
These results are also consistent with our previous be independently regulated, as might be needed in some
experimental systems or gene therapy applications. Thiswork demonstrating amplified expression of MDR1 and
of heterologous genes when cells are exposed to in- purpose is best served by two-gene vectors utilizing an
internal promoter which is tissue-specific or inducible increasing selective pressure with increasing concentra-
tions of colchicine (Kane et al., 1988, 1989). Neo is not some fashion. The promoters used in this study were all
considered constitutive and not tissue-specific, but Gazitgenerally considered to be an amplifiable gene, but it
has been reported as an amplifiable marker in bacteria et al. recently reported a HaMSV/MDR1 vector with a
GRP78 internal promoter controlling expression of neoand trypanosomes, under conditions that promote ho-
mologous recombination (Peterson and Rownd, 1983; (Gazit et al., 1995). Cells transduced with corresponding
retrovirus and selected with colchicine express neo un-ten Asbroek et al., 1993). A mutant (weak) neo gene
within a bovine papilloma virus vector can be amplified der conditions of low oxygen and low glucose, factors
that also induce the endogenous GRP78 gene. This sug-to high copy number in mouse L cells and Chinese
hamster ovary cells, in response to elevated selection gests that constitutive MDR1 expression does not pre-
vent inducible expression from a heterologous promoter.pressure (Niwa et al., 1991). Further experimentation is
under way to determine whether increasing the G418 GRP78-inducible neo expression also appears to be
maintained in vivo, according to this study, although thereselection pressure on our transduced K562 cells can
lead to enhanced expression of neo and of the MDR1 was no in vivo selection for MDR1 expression in those
experiments (Gazit et al., 1995).gene product.
Other HaMSV/MDR1-based bicistronic vectors have We did not obtain efficient expression from internal
promoters in KB-3-1 cells (Fig. 3 and Table 4). The reasonbeen reported (Sugimoto et al., 1994, 1995a,b; Aran et
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tection of murine recipients from drug toxicity by progeny of trans-for this is not known, but it appeared to be manifested
duced stem cells. Blood 75, 337–343.at the level of gene transcription. It could be that tissue-
Doroshow, J. H., Metz, M. Z., Matsumoto, L., Winter, K. A., Sakai, M.,
specific transcription factors were limiting in KB-3-1 cells. Muramatsu, M., and Kane, S. E. (1995). Transduction of NIH 3T3
This would be consistent with the low G418-based titers cells with a retrovirus carrying both human MDR1 and glutathione
S-transferase p produces broad-range multidrug resistance. Cancerand transduction efficiencies in KB-3-1 cells even in the
Res 55, 4073–4078.absence of any prior exposure to colchicine. Further work
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose,will be required to determine the basis for low expression
K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993).
in KB-3-1 cells, whether this is a species-specific or tis- Vaccination with irradiated tumor cells engineered to secrete murine
sue-specific phenomenon and whether the MDR1 or granulocyte-macrophage colony-stimulating factor stimulates potent,
specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci.HaMSV expression system is contributing to this result
USA 90, 3539–3543.in some cell types.
Gazit, G., Kane, S. E., Nichols, P., and Lee, A. S. (1995). Use of theTransduction efficiencies into KB-3-1 cells were also
stress-inducible grp78/BiP promoter in targeting high level gene ex-
low, whether colchicine or G418 was used to select pression in fibrosarcoma in vivo. Cancer Res. 55, 1660–1663.
transduced cells (Table 3). It seems to be a general phe- Ghattas, I. R., Sanes, J. R., and Majors, J. E. (1991). The encephalomyo-
carditis virus internal ribosome entry site allows efficient coexpres-nomenon that retroviral transduction is lower into human
sion of two genes from a recombinant provirus in cultured cells andcell lines than into mouse cell lines (Markowitz et al.,
in embryos. Mol. Cell. Biol. 11, 5848–5859.1988a; Miller et al., 1991). Nevertheless, another potential
Hanania, E. G., Fu, S., Roninson, I., Zu, Z., Gottesman, M. M., and
advantage of MDR1-based vectors for gene therapy is Deisseroth, A. B. (1995a). Resistance to taxol chemotherapy pro-
that in vivo selection could allow survival of even rare duced in mouse marrow cells by safety-modified retroviruses con-
taining a human MDR-1 transcription unit. Gene Ther. 2, 279–284.transduction events. If coupled with a pseudotyping ap-
Hanania, E. G., Fu, S., Zu, Z., Hegewisch-Becker, S., Korbling, M., An-proach to broadening host range (Burns et al., 1993) or
dreeff, M., Mechetner, E., Roninson, I., Giles, R., Berenson, R., Heim-a targeting approach to narrowing host range (Russell
feld, S., and Deisseroth, A. B. (1995b). Chemotherapy resistance to
et al., 1993; Young et al., 1990), the powerful MDR1 selec- taxol in clonogenic progenitor cells following transduction of CD34
tion system could have widespread utility for the long- selected marrow and peripheral blood cells with a retrovirus which
contains the MDR-1 chemotherapy resistance gene. Gene Ther. 2,term expression of any variety of therapauetic genes.
285–294.
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